Mogo Finance Technology is in the credit services industry and is part of the financial services sector. The company CEO is David Feller. Mogo Finance Technology Inc offers consumer fintech platforms having a suite of innovative financial products providing millennials solutions to help manage and improve financial health.



Previous Intraday Performance:

The MOGO shares had a previous change of -15.80% which opened at 3.77 and closed at 3.41. It moved to an intraday high of 3.77 and a low of 3.28.

SeekingAlpha:  Microcaps dominate midday movers

Historical Performance:

Over the last five trading days, MOGO shares returned -6.32% and in the past 30 trading days it returned 8.07%. Over three months, it changed 43.28%. In one year it has changed 29.80% and within that year its 52 week high was 4.05 and its 52 week low was 1.98. MOGO stock is 72.22% above its 52 week low.

Our calculations result in a 200 day moving average of 2.81 and a 50 day moving average of 3.07. Right now, MOGO stock is trading 21.43% above its 200 day moving average.

SeekingAlpha:  Microcaps dominate midday movers

Liquidity:

The company has a market cap of $80.7m with 23.7m shares outstanding and a float of 23.7m shares. Trading volume was 60,631 shares and has experienced an average volume of 26,227 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.17.

Below was the last reported quarterly diluted earnings per share:

4thQtr 2018Reported 05-14-2019: -0.16
3rdQtr 2018Reported 03-12-2019: -0.24
2ndQtr 2018 -0.20
1stQtr 2018 -0.13
4thQtr 2017 -0.26

Base on our calculations, the intrinsic value per share is 5.70, which means it might be undervalued and has a margin of safety of 40.20%.

The growth of the EPS is critical in understanding the current valuation of Mogo Finance Technology; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 13.10% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 20.10% of institutional ownership.

The beta was calculated to be 2.37.

SeekingAlpha:  Karyopharm Therapeutics misses by $0.23, misses on revenue

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -16.20%, profit margin is -38.64%, price-to-sales is 2.05 and price-to-book is 49.00.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 1  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here